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ABSTRACT 
Nitrogen-containing bisphosphonate (N-BP), including zoledronic acid (ZOL) and 
alendronate (ALD), have been proposed as sensitisers in γδ T cell immunotherapy in pre-
clinical and clinical studies. Therapeutic efficacy of N-BPs is hampered by their rapid renal 
excretion and high affinity for bone.  Liposomal formulations of N-B  have been proposed to 
improve accumulation in solid tumours. Liposomal alendronate (L-ALD) has been suggested 
as a suitable alternative to liposomal ZOL (L-ZOL), due to unexpected mice death 
experienced in pre-clinical studies with the latter. Only one study so far has proven the 
therapeutic efficacy of L-ALD, in combination with γδ T cell immunotherapy, after 
intraperitoneal administration of γδ T cell resulting in delayed growth of ovarian cancer in 
mice. This study aims to assess the in vitro efficacy of L-ALD, in combination with γδ T cell 
immunotherapy, in a range of cancerous cell lines, using L-ZOL as a comparator. The 
therapeutic efficacy was tested in a pseudo-metastatic lung mouse model, following 
intravenous injection of γδ T cell, L-ALD or the combination. In vivo biocompatibility and 
organ biodistribution studies of L-BPs were undertaken simultaneously. Higher 
concentrations of L-ALD (40-60 µM) than L-ZOL (3-10 µM) were required to produce a 
comparative reduction in cell viability in vitro, when used in combination with γδ T cells. 
Significant inhibition of tumour growth was observed after treatment with both L-ALD and 
γδ T cells in pseudo-metastatic lung melanoma tumour-bearing mice after tail vein injection 
of both treatments, suggesting that therapeutically relevant concentrations of L-ALD and γδ T 
cell could be achieved in the tumour sites, resulting in significant delay in tumour growth.  
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1. Introduction 
 
Circulating gamma delta (γδ) T cells represent 1-10% of all peripheral blood T lymphocytes 
[1] and predominantly express the Vγ9Vδ2 T cell receptor (TCR) [2]. They recognize non-
peptide phosphoantigens (PAgs) such as isopentyl pyrophosphate (IPP) [3]. In human cells, 
PAgs are generated via the mevalonate pathway, which is generally upregulated in 
transformed cells [4]. Vγ9Vδ2 T cells play an important role in cancer immunosurveillance 
[5] and have been used clinically in adoptive immunotherapy of cancer [6-11].  Sensitisation 
approaches in immunotherapy have been sought to improve therapeutic outcomes. Nitrogen-
containing bisphosphonates (N-BPs), such as zoledronic acid (ZOL) or alendronate (ALD), 
are known to inhibit farnesyl pyrophosphate (FPP) synthase, an enzyme in the mevalonate 
pathway, in cancer cells, causing intracellular accumulation of PAgs [12]. Exposure of 
Vγ9Vδ2 T cells to PAgs results in their activation via release of pre-formed perforin, 
granzymes and cytokines, and can lead to direct elimination of tumour cells [13].  
 
It has been shown that pre-treatment of tumour cells with low concentrations of N-BPs, can 
sensitise them to killing by Vγ9Vδ2 T cells, resulting in an overall additive or synergistic 
cytotoxicity in vitro [14-18], in vivo [19-26] and in clinical studies [8, 9, 27]. Therapeutic 
efficacy of N-BPs is hampered by their rapid renal excretion and high affinity for bone [28]. 
Improved pharmacokinetic profile and enhanced passive accumulation and retention within 
solid tumours has been achieved by encapsulation of ZOL and ALD into liposomes (L-ZOL 
and L-ALD) [29, 30]. L-ZOL was able to sensitise a number of ovarian cancer cell lines to 
destruction by Vγ9Vδ2 T cells in vitro [23]. However, its use in vivo was prohibited by the 
profound toxicity and sudden mice death [23, 29].  Several studies have reported the use of L-
ALD for therapeutic applications in cancer [31] and inflammatory conditions [32-35] pre-
clinically. L-ALD has been shown to be effective when used with Vγ9Vδ2 T cells in an 
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ovarian cancer model in vivo [23]. A clinical study is due to commence to evaluate the use of 
L-ALD in preventing coronary artery restenosis [36].  
 
While several studies have [31, 37-39] reported the use of L-ALD or L-ZOL as a 
monotherapy in cancer models only one previous study has explored L-ALD in combination 
with γδ T cells in tumour mouse model, following local (IP) administration of γδ T cells to 
treat ovarian tumours [23]. In this study we hypothesise that systemic administration of γδ T 
cells is able to result in significant tumour growth delay when combined with L-ALD therapy 
in a pseudo-metastatic lung melanoma model. Additionally, the in vivo toxicity and 
biodistribution of L-ZOL and L-ALD has not been directly compared before. The aim of this 
study is to evaluate the in vitro potency, in vitro and in vivo efficacy of liposomal alendronate 
in combination with γδ T cell immunotherapy in cancerous cell lines and mice, respectively.  
In addition to efficacy studies, whole body organ biodistribution and in vivo toxicity were 
performed, bringing this formulation a step further towards biopharmaceutical development 
and evaluation in pre-clinical models. 
 
2. Materials and Methods 
2.1 Materials 
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and 1,2-dipalmitoyl 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt) 
(DSPE-PEG2000) were obtained from Lipoid (Germany). 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-diethylenetriaminepentaacetic acid (ammonium salt)  (DSPE-
DTPA) was purchased from Avanti Polar Lipids, Inc (USA). Dextrose, cholesterol, sodium 
chloride, phosphate buffered saline (PBS) tablet, N-(2-Hydroxyethyl)piperazine-N′-(2-
ethanesulfonic acid) (HEPES), methanol (Analytical reagent grade), chloroform (Analytical 
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reagent grade), isopentane (analytical reagent grade), diethyl ether (analytical reagent grade) 
and Sephadex G75 were purchased from Sigma (UK). Zoledronic acid was a kind gift from 
Novartis (Switzerland). PD-10 desalting column was obtained from GE Healthcare Life 
Sciences (UK). Snake Skin® dialysis tubing (MWCO 10000 Da) was purchased from 
Thermo-fisher (USA). Dulbecco’s modified Eagle’s medium (DMEM), Glutamax™ and 
antibiotic-antimycotic solution were purchased from Invitrogen (UK). Foetal Bovine Serum 
(FBS) was purchased from First Link (UK). Thiazolyl blue tetrazolium bromide (MTT) and 
alendronate sodium trihydrate, were obtained from Alfa Aesar (UK). DMSO was obtained 
from Fisher (UK). Human IFN-γ ELISA Ready-set-go kit was purchased from eBiosciences 
(UK). Mouse TNF (Mono/Mono) ELISA set was purchased from BD Biosciences (USA). 
Indium-111 chloride was obtained from Mallinckrodt (NL). Thin layer chromatography 
(TLC) strips for radio-labeling were purchased from Agilent Technologies UK Ltd (UK). 
Isoflurane (IsoFlo®) for anaesthesia was purchased from Abbott Laboratories Ltd (UK). All 
reagents were used without further purification. 
 
2.2 Preparation of Liposomes 
Liposomes were prepared using the thin film hydration (TFH) method. DSPC, cholesterol 
and DSPE-PEG2000 (55:40:5 molar volume) were added to a 25 ml round-bottom flask and 
2 ml chloroform/methanol (4:1 v/v) was added. A thin lipid film was formed upon removal of 
the solvent under reduced pressure using a rotary evaporator (Rotavapor® R-210, Buchi UK). 
The lipid film was flushed with nitrogen to remove any remaining traces of organic solvent. 
The lipid film was then hydrated with 1 ml of PBS, adjusted to pH 7.4.  The liposome 
suspension was left for 1 h at 60°C and was vortexed (Vortex genie 2, Scientific Industries 
Inc, USA) every 15 min [40]. The resulting suspension was stored at 4°C. The size and 
polydispersity (PDI) of the liposomes were reduced with serial extrusion steps. The liposome 
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suspension was extruded using the mini-extruder (Avanti Polar Lipids, USA) through 
polycarbonate membranes (Avanti Polar Lipids, USA) with pore sizes 0.8 µm (5x), 0.2 µm 
(5x), 0.1 µm (10x) and 0.08 µm (15x), above the phase transition temperature for the lipid. 
When formulating L-ZOL and L-ALD, the lipid films were hydrated with either 100 mM 
ZOL or 100 mM ALD in HEPES Buffered Saline (HBS; 20 mM HE ES and 150 mM NaCl, 
pH 7.4), and free ZOL and ALD was removed by dialysis against HBS using a 10000 Da 
MWCO dialysis bag. Liposomes were prepared at a final lipid concentration of 25 mM. 
 
2.3 Cancer cell line culture conditions 
The cell lines PANC-1 (CRL-1469™), PANC0403 (CRL-2555™) and were obtained from 
ATCC®. A375Ppuro and A375Pβ6 cell lines were created using the human melanoma cell 
line A375P (CRL-3224™), which was infected with pBabe retroviruses encoding puromycin 
resistance alone (A375Ppuro) or in combination with cDNA for human β6 integrin 
(A375Pβ6), as previously reported [41]. The A375Ppuro and A375Pβ6 were a kind gift from 
Dr. John Marshall (QMUL). All cell lines were maintained at 37°C, 5% CO2 and 5% relative 
humidity. Advanced RPMI or DMEM media were used, both of these were supplemented 
with 10% FBS, 1% Glutamax and 1% Penicillin/Streptomycin. 
 
2.4 Treatment of cancer cell lines with N-BPs in monotherapy studies 
The cell lines A375Ppuro and PANC-1 were seeded in a 96-well plate at a seeding density of 
10,000 cells/well. Cells were treated with 0.01-100 µM ZOL or ALD, 20-200 µM EL or were 
left untreated. After 24, 48 or 72 h incubation, the cell viability was assessed with MTT, as 
described below. 
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2.5 Treatment of cancer cell lines with N-BPs/ liposomal N-BPs and γδ T cells in 
combination therapy studies 
The cell lines A375Ppuro, A375Pβ6, PANC-1 and PANC0403 were seeded at 50,000 
cells/well in a 96-well plate. Confluent monolayers of each cancer cell line were treated for 
24 hours with ZOL ALD, L-ZOL or L-ALD at concentrations of 3-10 µM (ZOL and L-ZOL), 
40-60 µM (ALD and L-ALD) or were left untreated.  With regards to L-ZOL and L-ALD, the 
concentrations used indicate the amount of encapsulated ZOL and ALD after purification. As 
a control, cells were also treated with EL at concentrations of 36.5-219 µM After 24 hours, 
the treatments were removed and the monolayers were then co-cultured with 2.5 x 10
5 
ex vivo 
expanded γδ T cells (or γδ T cell culture media as a control) per well for a further 24 hours. 
Cell viability was assessed with MTT as described below. 
 
2.6 MTT assay 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) solution was prepared 
in PBS at a concentration of 5 mg/ml and was diluted in media (1:6 v/v) prior to use. The 
supernatant of each well was removed and MTT solution (120 µl) was added to each well. 
The plates were then incubated at 37°C and 5% relative humidity for 3 hours. The MTT 
solution from each well was removed and DMSO was added to solubilise (200 µl/well for 96 
well) the crystals formed and this was incubated for 5 min at 37°C, to eliminate entrapped air 
bubbles. The absorbance was read at 570 nm with subtraction readings at 630 nm to 
normalise for cell debris (FLUOStar Omega, BMG Lab Tech). Percentage cell viability (%) 
was calculated as a percentage of untreated cells (equation in SI). Cell viability was 
expressed as mean ± standard deviation (n=5).  
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2.7 Determination of IFN-γ concentration with ELISA 
Supernatant from the co-culture assay was removed from each of the wells immediately 
before the cytotoxicity assay was performed. The supernatant was centrifuged to remove the 
γδ T cells and was stored at -80°C until required. Supernatants were diluted 1:40 and 
analysed using a human IFN-γ ELISA Ready-set-go-kit as per the manufacturer’s protocol.  
 
2.8 Radiolabelling of liposomes 
DSPC: cholesterol: DSPE-PEG2000:DSPE-DTPA (54:40:5:1 molar ratio) liposomes were 
prepared with the TFH method, as described above, then radiolabelled with 
111
In [42]. 
Briefly, the required volume of 
111
In, containing 1 MBq or 10-15 MBq per mouse for gamma 
counting or SPECT/CT imaging studies, respectively, was added to 2 M ammonium acetate 
buffer (one-ninth of the reaction volume, pH 5.5). This was then added to the liposome 
sample (100 μl of 20 mM liposomes/mouse) to give a final ammonium acetate concentration 
of 0.2 M. The mixture was incubated for 30 min at room temperature with vortexing every 10 
minutes. The reaction was quenched by the addition of 0.1M EDTA solution to the mixture 
(5% v/v of the reaction mixture) to chelate free 
111
In. Unbound 
111
In:EDTA was removed 
using NAP-5 desalting columns equilibrated with PBS with the liposomes collected in 
fractions 1-3 (~150 μl per injection dose).  
 
2.9 Efficiency and stability of the radiolabelling in serum 
Samples of the radiolabelled liposomes or 
111
In:EDTA were spotted in glass microfibre 
chromatography paper impregnated with silica gel. These strips were then developed using a 
mobile phase of 50 mM EDTA in 0.1 M ammonium acetate. Strips were placed on a multi-
purpose storage phosphor screen (Cyclone ®, Packard, Japan) and kept in an autoradiography 
cassette (Kodak Biomax Cassette ®) for 10 min. Quantitative autoradiography counting was 
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then carried out using a cyclone phosphor detector (Packard ®, Australia). The labelling 
stability was tested by incubation of the radio-conjugates in the presence or absence of foetal 
bovine serum (FBS). Samples were diluted in 50% FBS or PBS [1:2 (v/v)], and incubated for 
24 h at 37°C. The percentage of 
111
In (immobile spot) still conjugated to the liposomes was 
evaluated by TLC, using the same protocol, as described above. 
 
2.10 Animal models 
All animal experiments were performed under the authority of project and personal licences 
granted by the UK Home Office and the UKCCCR Guidelines (1998). Male NOD SCID 
gamma (NSG) mice (~20 g), 4-6 weeks old, were obtained from Charles River (UK). 
Subcutaneous (s.c.) tumours were established by injecting 5 x 10
6
 cells A375Pβ6 in 100 μl 
PBS into each of the rear-flanks of the mouse. The size of the tumour was measured using 
callipers and tumour area and volume could then be determined using the equation Tumour 
volume = width*width*length*(3.14/6). Experiments were performed when tumours reached 
~ 300 mm
3
. 
 
2.11 In vivo toxicity studies of L-ALD and L-ZOL in NSG mice after a single injection 
Non-tumour bearing NSG mice were intravenously injected with 0.1 µmol L-ZOL or 0.5 
µmol L-ALD. After 72 h, the mice were sacrificed and the toxicity of L-ZOL and L-ALD 
assessed using the methods below. 
2.14.1 Spleen Weight 
The spleens were excised from each mouse and weighed using a laboratory balance 
(GeniusME, Sartorius, Germany).  
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2.14.2 Haematological Profile 
Whole blood samples were obtained via cardiopuncture using K2EDTA as an anti-coagulant. 
Fresh blood smears were made using 5 µl blood and the haematological profiles of these 
samples were performed by the Royal Veterinary College (London, UK).  
2.14.3 Serum Biochemistry 
Serum was obtained from some of whole blood samples by allowing the blood to clot and 
centrifuging at for 15 minutes at 1500 g. The serum biochemistry profiles were performed by 
the Royal Veterinary College (London, UK). 
2.14.4 TNF-α serum levels 
TNF-α ELISA was performed on serum samples (diluted 1:3) using a mouse TNF-α 
(Mono/Mono) ELISA set as per the manufacturer’s protocol. 
2.14.5 Organ Histology 
Organs were immediately fixed in 10% neutral buffer formalin as 5 mm
2
 pieces. These pieces 
were then paraffin-embedded and sectioned for haematoxylin and eosin stains (H&E) 
according to standard histological protocols at the Royal Veterinary College. The stained 
sections were analysed with a Leica DM 1000 LED Microscope (Leica Microsystems, UK) 
coupled with CDD digital camera (Qimaging, UK).  
2.14.6 Survival 
Mice were injected with 0.1 µmol L-ZOL (n=2) or 0.5 µmol L-ALD (n=10) and observed for 
weight loss and overall appearance daily.  
 
2.12 In vivo toxicity of L-ALD in NSG mice after multiple injections 
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Non-tumour bearing NSG mice were injected with at one week intervals with 0.5 µmol L-
ALD for a total of three doses. The blood, serum and organs of the mice were analysed as 
above, with the mice sacrificed 72 h after the final injection. 
 
2.13 Whole body SPECT/CT imaging of radiolabelled liposomes in A375Pβ6-tumour 
bearing mice 
Each mouse was injected with radiolabelled liposomes at 2 μmol each, containing 1 MBq or 
10-15 MBq, for biodistribution and SPECT/CT studies, respectively, via tail vein injection. 
Mice were imaged with nanoSPECT/CT scanner (Bioscan ®, USA) at different time points; 
immediately after the i.v. administration (0-30 min), 4 h and 24 h. For each mouse, a 
tomography was initially done (45 Kvp; 1000 ms) to obtain parameters required for the 
SPECT and CT scanner, including the starting line, finish line and axis of rotation of the 
acquisition. SPECT scans were obtained using a 4-head scanner with 1.4 mm pinhole 
collimators using the following settings: number of projections: 24; time per projection: 60 
sec and duration of the scan 60 min. CT scans were obtained at the end of each SPECT 
acquisition using 45Kvp. All data were reconstructed with MEDISO (medical Imaging 
System) and the combining of the SPECT and CT acquisitions were performed using 
PMOD® software. 
 
2.14 Gamma scintigraphy of radiolabelled liposomes in A375Pβ6-tumour bearing mice 
After 24 h, mice were sacrificed and the major organs (brain, lung, liver, spleen, kidney, 
heart, stomach and intestine), muscle, skin, bone (Femur), carcass and tumours were 
collected, weighed and placed in scintillation vials. Additionally, 5 μl blood samples were 
collected at various time points (5, 10, 30, 60, 240 and 1440 minutes). Each sample was 
analysed for [
111
In] specific activity using an automated gamma counter (LKB Wallac 1282 
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Compugamma, PerkinElmer, UK) together with dilutions of injected dose with dead time 
limit below 60%. The gamma rays emitted by the radioisotope were detected, quantified and 
corrected for physical radioisotope decay by the gamma counter. Radioactivity readings 
(counts per minute- CPM) were plotted as percentage of injected dose per organ (%ID/organ) 
or percentage of injected dose per gram of tissue (%ID/g). The data were expressed as the 
mean of triplicate samples ± SD.  
 
2.15 Therapy study 
Male NSG mice (4-6 weeks) were inoculated with 5 x 10
6 A375Pβ6.luc by i.v injection to 
form pseudo-metastatic lung tumours. Bioluminescence imaging of mice was carried out on 
Day 6 as described above and mice were divided into 4 treatment groups: naïve, L-ALD, γδ T 
cells and L-ALD and γδ T cells combination treatment. Doses used in therapy experiments 
were 0.5 µmol of ALD/mouse (L-ALD) and 1 x 10
7
 cells/mouse (γδ T cells), all injected via 
the tail vein.   Three doses of each treatment were given at one week intervals on days 7, 14 
and 21. In the case of the combination treatment, mice were pre-injected with L-ALD (days 
6, 13, and 20) then injected with γδ T cells (days 7, 14, and 21).  Tumour growth was 
monitored by bioluminescence imaging twice weekly (days 6, 10, 13, 17, 20, 24, 27), as 
described above.  
 
2.16 Determination of IFN-γ concentration with ELISA 
Animals from the therapy study were sacrificed and sera was analysed for human IFN-γ. Sera 
were diluted 1:2 and analysed using a human IFN-γ ELISA Ready-set-go-kit as per the 
manufacturer’s protocol.  
 
2.15 Statistics 
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For all experiments, data were presented as mean ± SD, where n denotes the number of 
repeats. Independent variable Student t tests were performed using IBM SPSS version 20 for 
in vitro cytotoxicity studies. For in vivo studies, significant differences were examined using 
one-way ANOVA. The t-value, degrees of freedom and two-tailed significance (p-value) 
were determined. * p< 0.05, ** p< 0.01 and *** p< 0.001. 
3. Results  
3.1 L-ZOL and L-ALD of comparable size and drug loading were prepared  
L-ZOL and L-ALD composed of DSPC:cholesterol:DSPE-PEG2000 (55:40:2 molar ratio) 
were formulated using the Thin Film Hydration (TFH) method (Figure S1), extruded and 
purified using dialysis. Liposomes were also prepared using the reverse phase evaporation 
(RVE) method as a comparison, but as liposomes produced by the two methods had the same 
characteristics. TFH method was used to produce liposomes for all subsequent experiments. 
Liposomes exhibited a hydrodynamic size of 155.4 – 159.0 nm, with narrow polydispersity 
index (PDI of 0.045-0.104) and slightly negative zeta potential (-11.7 to -14.0 mV) (Table 
S1).  Methods were developed to quantify the amount of ZOL and ALD encapsulated into 
liposomes, as described in the supplementary information, using UV-Vis or HPLC (for ZOL 
quantification) (Figure S2), copper sulphate-based UV spectroscopy method or o-
phthalaldehyde (OPA)-based fluorescence methods (for ALD quantification) (Figure S3). 
Our results showed that both ZOL and ALD had similar encapsulation efficiencies (% EE) 
ranging from 5.2 – 6.4% (Table S2). Drug loading of 0.23 – 0.27 mmol ZOL or ALD per 
mmol lipid was obtained (p> 0.05).  
 
3.2 In vitro anti-tumour activity of ZOL is more potent than ALD  
The cytotoxicity of ZOL and ALD as a monotherapy was assessed using the melanoma cell 
line A375Ppuro and the pancreatic cell line PANC-1. Additionally empty liposomes (EL) 
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were tested as controls. These results would enable non-toxic ranges of both N-BPs and EL to 
be established for use in co-culture studies with γδ T cells. ZOL and ALD were tested in the 
range of 0.01 – 100 µM for 24, 48 and 72 hours of incubation. Time- and dose-dependent 
cytotoxicity was elicited by both N-BPs. Cell viability results for 24, 48 and 72 h are shown 
in Figures S5 and S6. In order to compare the cytotoxicity of the two N-BPs, cell viability at 
72 h was used to calculate the IC50 values for ZOL and ALD in the two cell lines (Figure 1). 
IC50 values of ZOL were 18.86 µM and 55.98 µM for A375Ppuro and PANC-1, respectively. 
IC50 values of ALD were 37.92 µM and 106.9 µM for same cell lines.  It was concluded that 
PANC-1 cells were more resistant than A375Ppuro to the direct cytotoxic action of N-BPs. 
Moreover, ZOL was more potent that ALD in both cell lines. ZOL and ALD concentration 
ranges selected for co-culture studies with γδ T cells were 3 – 10 µM and 40 – 60 µM, 
respectively. It is worth mentioning that such high IC50 values for both drugs suggests that 
neither is suitable for use as an anti-cancer agent for non-osseous tumours. 
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Figure 1: IC50 values of N-BPs after 72 h incubation for different human cancer cell lines.  The 
IC50 values were determined for the melanoma cancer cell line A375Ppuro and the pancreatic cancer 
cell line PANC-1 incubated with (A) ZOL or (B) ALD for 72 h. IC 50 are in the order of PANC-1 > 
A375Ppuro for both ALD and ZOL.  Higher IC50 values were obtained for ALD than ZOL. R
2
 values 
of 0.9988 (ALD PANC-1 and ZOL A375Ppuro). 0.9736 (ALD A375Ppuro) and 0.9718 (ZOL PANC-
1) were obtained. Data was expressed as mean ± SD (n=5).  
In case of EL, a reduction in cell viability of PANC-1 was observed at concentrations > 200 
µM with cell viabilities of 87.0 ± 1.5 % and 87.9 ± 8.8 % after 48 and 72 h, respectively 
(Figure S7).  A375Ppuro cells proved more sensitive to non-specific toxic effects of EL with 
cell viabilities of 72.5 ± 5.7 % and 45.5 ± 3.4 % under similar treatment conditions (Figure 
S7). In co-culture studies with γδ T cells, cancer cells will be treated with liposomal 
formulations for only 24 h at concentrations < 40 µM (ZOL) and < 240 µM (ALD), after 
which the drug is removed. Cells will be further incubated for 24 h with γδ T cells. This 
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incubation protocol is unlikely to result in significant non-specific toxicity from the carrier 
itself.  
 
3.4 L-ZOL and L-ALD can sensitise cancer cells to destruction by γδ T cells in co-
culture studies 
Free and liposomal N-BPs were then used in combination with γδ T cells, to assess whether 
pre-treating the cells with the N-BPs would sensitise cancer cells for destruction by γδ T 
cells. The isolation and expansion protocol used to generate and characterise Vγ9Vδ2 T cells 
is described in supplementary information (Figure S8 and S9). In this experiment, two 
melanoma (A375Ppuro and A375Pβ6) and two pancreatic (PANC-1 and PANC0403) cancer 
cell lines were used. Each pair of cells included an αvβ6 integrin positive and negative cell 
line to allow for future use of targeted liposomes. We hypothesise that free and liposomal N-
BPs or γδ T cells are not toxic to cancer cells when used individually under the conditions 
tested, but their pre-treatment with BPs sensitize them to killing by γδ T cells. A scheme of 
the treatment protocol is shown in Figure S10.   
 
Initial experiments focused on ZOL and L-ZOL. As expected, ZOL, L-ZOL or γδ T cells 
exerted no cytotoxic effect against these tumour cells when used individually, at previously 
determined sub-toxic concentrations (black bars, Figure 2).   By contrast, a significant and 
dose-dependent reduction in cell viability was seen when free ZOL or L-ZOL was used to 
sensitise tumour cells to subsequent addition of Vγ9Vδ2 T-cells. This toxic effect was more 
evident with free ZOL than with L-ZOL (grey bars, Figure 2). In keeping with this, 
PANC0403 cells appeared to be resistant to L-ZOL/γδ T cells combination therapy, whereas 
free ZOL could effectively sensitise these tumour cells. 
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Figure 2: Viability of human cancer cell lines after incubation with γδ T cells and L-ZOL. Cells 
were treated with ZOL or L-ZOL for 24h at concentrations between 3-10 µM. The treatments were 
then removed and replaced with 2 x 10
5
 γδ T cells for an additional 24h, before an MTT assay was 
performed to determine residual tumour cell viability. The ZOL and L-ZOL were used at non-toxic 
concentrations, in the absence of γδ T cells. No background toxicity was found for γδ T cells without 
N-BP. However, a dose dependent toxicity was found in cells pre-treated with ZOL or L-ZOL (ZOL> 
L-ZOL), except for PANC0403. Data was expressed as mean ± SD (n=5). *p < 0.05, (Student’s t test 
vs. naive). 
 
Next, we evaluated the ability of ALD or L-ALD to sensitise tumour cells to Vγ9Vδ2 T-cells. 
In agreement with cell viability studies using N-BPs as monotherapy, higher concentrations 
of ALD and L-ALD than for ZOL, were required to induce reductions in cancer cell viability 
in the co-cultures.  Cell viabilities of 5 – 37 % and 55 – 93 % were obtained for ALD and L-
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ALD, respectively, when used with γδ T cells treatment, at 40-60 µM ALD (grey bars, 
Figure 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Cell viability of human cancer cell lines after incubation with γδ T cells and L-
ALD. Cells were treated with ALD or L-ALD for 24h at concentrations between 40-60 µM. These 
agents were then removed and replaced with 2 x 10
5
 γδ T cells for an additional 24 h, before an MTT 
assay was performed to measure residual tumour cell viability. The ALD and L-ALD were used at 
non-toxic concentrations, in the absence of γδ T cells. No background toxicity was found for γδ T 
cells without N-BP. However, a non-dose dependent toxicity, in the range tested, was found in 
cells pre-treated with ALD or L-ALD (ALD> L-ALD). Data was expressed as mean ± SD (n=5). *p < 
0.05, (Student’s t test vs. naive). 
 
 
Unlike ZOL and L-ZOL, no dose-dependency was observed in the case of ALD or L-ALD 
treatment, possibly due to the narrower range used than in the ZOL study. A slight but 
significant reduction in cell viability was observed when cells were treated with free ALD, in 
some of the conditions, despite the absence of γδ T cells (~60-90% % cell viability, p <0.05). 
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This is presumably due to the high ALD concentrations used compared to ZOL. No reduction 
in cell viability was found when cells were pre-treated with EL and then γδ T cells, at 
equivalent concentrations used with the drug (Figure S11).  These studies further confirmed 
that the reduction in cancer cell viability is specific to N-BPs ability to sensitise cells to 
γδ T cells.  It was also concluded that free N-BPs can sensitive cancer cells more efficiently 
than their liposomal formulations. This is not surprising as encapsulation of the drug within 
liposomes is likely to slow down its release (Figure S4), causing a delayed onset of action in 
vitro as has been reported for other drugs [43]. 
 
3.5 Interferon (IFN)-γ production is increased proportionally to cell kill 
The IFN-γ concentrations in the co-culture supernatants were measured in order to further 
confirm that cell kill was specific to γδ T cell activation. In all cases, the use of free N-BPs 
with γδ T cells led to a significant increase in IFN-γ levels compared to γδ T cells treatment 
alone (18 – 27  vs. ~10 ng/ml) (Figure 4). Agreeing with the cell viability results, IFN-γ 
levels were approximately two-fold higher in cells pre-treated with free ZOL or ALD than 
their liposomal formulations (Figure 4).  Only some L-ZOL or L-ALD treatment groups 
showed significant increases in IFN-γ levels, but in a random manner. The good correlation 
between cell viability and IFN-γ concentration suggests that cell kill is due to the activation 
of γδ T cells.  
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Figure 4: IFN-γ production by γδ T cells after incubation with cancer cells. IFN-γ ELISA was 
performed on supernatant removed from the co-culture experiment, prior to the MTT assay, for each 
of the cancer cell lines. The quantity of IFN-γ produced by the γδ T cells for each of the different pre-
treatment conditions is expressed as ng/ml. Free ZOL or ALD led to an increased production of IFN-γ 
compared to γδ T cells incubated with untreated cells. Pretreament with L-ZOL or L-ALD led to a 
smaller or no increase in IFN-γ production. Data was expressed as mean ± SD (n=3). *p < 0.05, **p < 
0.01, ***p < 0.001.  (Student’s t test vs. γδ T cells alone).  
 
3.6 In vivo toxicity of L-ZOL and L-ALD following a single injection in NOD scid 
gamma (NSG) mice 
It has been reported by Shmeeda et al., that L-ZOL resulted in sudden death of mice 
(BALB/c and Sabra) when used in vivo [29]. The use of L-ZOL and L-ALD in NSG mice has 
not been reported. NSG mice have been increasingly used for in vivo studies and may have 
different profiles to other mouse strains, as they are more immunocompromised. In the work, 
we used immunocompromised mice, as the aim is to be able to perform therapy study against 
human cancers in combination with human γδ T cells, using these mice. Immuno-competent 
0
5
10
15
20
25
30
35
n
g
/ 
m
l
0
5
10
15
20
25
30
35
n
g
/ 
m
l
0
5
10
15
20
25
30
35
n
g
/ 
m
l
0
5
10
15
20
25
30
35
n
g
/ 
m
l
PANC-1A375Ppuro
PANC0403
A375Pβ6
+ γδ T cells + γδ T cells
*** ** ** ** **
*** *** *** *** **
* * *** ****
** *** ** * **
***
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
21 
 
mice could not be used to grow human tumours or to inject γδ T cells, hence were not used. 
In this study, a direct comparison was conducted for L-ZOL and L-ALD using the parameters 
outlined in Shmeeda et al, following a single injection. Based on IC50 values obtained in 
vitro, a 5-fold higher dose of L-ALD (0.5 µmol ALD/ mouse) than L-ZOL (0.1 µmol 
ZOL/mouse) was used in vivo. Mice were sacrificed 72 h post single i.v. injection of 
liposomal N-BPs (L-N-BPs: L-ZOL or L-ALD), since in previous studies mice death was 
observed at 5 days L-ZOL post-injection. Parameters monitored and findings obtained are 
detailed below.  
3.6.1 Injection of L-ZOL or L-ALD leads to splenomegaly 
Spleens of mice injected with L-ZOL weighed significantly more (0.06 ± 0.02 g) than those 
of control mice (0.03 ± 0.004 g) (p < 0.01) (Figure 5A). Additionally, the spleens of mice 
injected with L-ALD also displayed significant splenomegaly vs. control spleens (0.06 ± 0.01 
g, p < 0.001).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Effects of L-ZOL and L-ALD on blood counts and spleen. NSG mice were injected with 
0.1 µmol L-ZOL or 0.5 µmol L-ALD. After 72 h, the mice were sacrificed. (A) The spleen was 
removed and weighed. A significant increase in spleen weight could be seen in the case of both L-
ZOL and L-ALD.  Blood counts were performed by automatic counting. An increase in (B) WBC and 
(C) % Neutrophils was seen when injected with L-ZOL or L-ALD, while a decrease in (D) % 
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Lymphocytes was observed. (Data were expressed as mean ± SD (n=10 and n=5 for spleen weight 
and blood counts, respectively) *p< 0.05, **p< 0.01, ***p< 0.001.  (Student’s t test vs. naive). 
3.6.2 Haematological analysis  
 It has been suggested that the systemic toxicity of L-ZOL in mice is haematologically related 
[29].  Changes in the full blood count profiles have previously been reported for L-ZOL. 
Additionally, N-BPs are known to have macrophage depleting effects. Agreeing with the 
previously reported results, L-ZOL caused leucocytosis, neutrophilia and lymphocytopenia 
(Figure 5B-D). White blood cells count and % neutrophils increased from 0.77 ± 0.15 x 
10
9
/L and 66.2 ± 7.9 % in control mice to 3.22 ± 2.49 x 10
9
/L (p< 0.01) and 92.2 ± 4.3 % (p< 
0.001), in L-ZOL group. Matching profiles for L-ZOL and L-ALD were obtained.  The 
complete haematological profile for L-ZOL and L-ALD is shown in Table 1. 
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Table 1: Haematological results
a
 from male non-tumour bearing NSG mice treated with a single 
dose of 0.1 µmol L-ZOL or 0.5 µmol L-ALD and sampled 72 h after dosing
b
 
 
Control
c
 L-ZOL
c
 L-ALD
c
 
 
Mean ±  SD  Range Mean ±  SD  Range Mean ±  SD  Range 
WBC 0.8 ± 0.2 0.6 – 1.0 3.2 ± 2.5**  1.3 – 3.2 2.2 ± 0.5*** 1.7 – 2.8 
Neutrophils 0.5 ± 0.1 0.4 – 0.7 3.0 ± 2.5** 1.3 – 2.8 2.0 ± 0.5*** 1.5 – 2.6 
Neutrophils % 66.2 ± 7.9 66.0 – 76.0 92.2 ± 4.3*** 87.0 – 97.0 88.6 ± 3.7*** 83.0 – 91.0 
Lymphocytes 0.2 ± 0.1 0.1 – 0.2 0.1 ± 0.1 0.0 – 0.2 0.1 ± 0.1 0.0 – 0.2 
Lymphocytes % 21.0 ± 10.4 10.0 – 22.0 3.0 ± 1.7** 2.0 – 6.0 5.2 ± 2.2* 2.0 – 8.0 
Monocytes  0.1 ± 0.1 0.0 – 0.2 0.1 ± 0.1 0.0 – 0.1 0.1 ± 0.1 0.1 – 0.2 
Monocytes % 10.6 ± 7.9 3.0 – 23.0 3.8 ± 3.0 1.0 – 8.0 6.0 ± 3.4 3.0 – 11.0 
Eosinophils 0.0 ± 0.0 0.0 – 0.0 0.0 ± 0.0 0.0 – 0.0 0.0 ± 0.0 0.0 – 0.0 
Eosinophils % 2.2 ± 1.3 0.0 – 3.0 1.0 ± 1.2 0.0 – 3.0 0.2 ± 0.4* 0.0 – 1.0 
Basophils 0.0 ± 0.1 0.0 – 0.1 0.0 ± 0.0 0.0 – 0.0 0.0 ± 0.0 0.0 – 0.0 
Basophils % 3.7 ± 5.1 0.0 – 9.8 0.0 ± 000 0 .0 – 0.0 0.0 ± 0.0 0.0 – 0.0 
RBC 7.7 ± 0.6 7.1 – 8.7 8.0 ± 0.4 7.4 – 8.4 7.9 ± 0.5 7.3 – 8.4 
HGB 13.0 ± 1.2 12.1 – 14.8 13.5 ± 0.7 12.6 – 14.3 12.7 ± 0.6 12.0 – 13.3 
HCT 43.0 ± 4.3 38.2 – 49.1 44.2 ± 1.6 42.2 – 45.6 42.0 ± 2.4 38.8 – 44.3 
MCV 56.1 ± 1.9 53.4 – 58.7 55.3 ± 1.5 53.6 – 57.6 52.9 ± 0.5** 52.6– 53.7 
MCH 17.0 ± 0.4 16.2 – 17.3 16.9 ± 0.4  16.4 – 17.5 16.0 ± 0.3** 15.7 – 16.3 
MCHC 30.2 ± 1.0 29.4 – 31.7 30.5 ± 0.8  29.4 – 31.4 30.3 ± 0.4 29.9 – 30.8 
RDW 14.6 ± 0.6 13.7 – 15.2 14.7 ± 0.4 14.0 – 15.0 14.6 ± 0.2 14.3 – 14.7 
PLT 1331.0 ± 104.2 1179 – 144 1223.4 ± 194.2 1023 – 1501 1472. ± 145.7 1232 – 1572 
PCV 35.4 ± 5.2 34.0 – 44.0 36.0 ± 2.7 32.0 – 39.0 35.4 ± 2.1 34.0 – 39.0 
 
 
 
 
 
 a Values are means ± SD (n=5)  
 b Abbreviations and units: WBC, white blood cell, 10e9/L; Neutrophils, 10e9/L; Lymphocytes, 10e9/L; 
Monocytes, 10e9/L; Eosinophils, 10e9/L; Basophils, 10e9/L; RBC, red blood cells, 10e12/L; HGB, 
haemoglobin, g/dL; HCT, haematocrit, %; MCV, mean cell volume, fL; MCH, mean cell haemoglobin, pg; 
MCHC, mean cell haemoglobin concentration, g/dL; RDW, rec cell distribution width, %; PLT, platelets, 
10e9/L; PCV, packed cell volume, %. 
c Data was expressed as means ± SD (n=5) *P < 0.05, **P < 0.01, ***P < 0.001.  (Sudent’s t test vs. naive).  
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3.6.3 Serum biochemistry profile  
The biochemistry profile of mice injected with L-ZOL or L-ALD was studied. Mild but non-
significant hypocalcaemia and elevated Blood Urea Nitrogen (BUN) were previously 
reported for L-ZOL [29].  The complete serum biochemistry profiles are shown in Table S3. 
In our study, L-ZOL and L-ALD did not display any significant differences to each other or 
to control mice. L-ZOL (6.78 ± 0.69 mmol/L) however resulted in small but significant 
reduction in urea compared to the control (8.42 ± 0.97 mmol/L) (p < 0.05). Additionally, L-
ALD (27.60 ± 1.67 g/L) led to a significant reduction in albumin levels compared to control 
mice (31.6 ± 1.67 g/L) (p < 0.01).  
3.6.4 TNF-α levels are not increased in mice treated with L-ZOL or L-ALD 
It has been shown the L-ZOL can cause a moderate non-significant increase in TNF-α levels 
in vivo [29]. An ELISA was performed on the serum to determine TNF-α levels. Mice 
injected with L-ZOL and L-ALD did not result in detectable levels of TNF-α in serum. As a 
positive control, serum from LPS challenged mice were also tested and produced TNF-α 
levels of 1.6 ng/ml. This difference may be due to the mice been sacrificed at an earlier 
timepoint than in the reported study, or due to the different strain of mouse used. 
3.6.5 No histological abnormalities seen in mice post i.v. injection of L-ZOL or L-ALD 
Histological examination of the major organs (heart, lung, liver, spleen and kidney) with 
H&E staining showed no obvious histological changes compared to control animals (Figure 
S12), agreeing with the published study on L-ZOL [29].  
 
3.6.6 Mice treated with L-ZOL but not L-ALD experience sudden death 5 days post injection 
Death of mice injected with L-ZOL (0.1 µmol ZOL), without warning sign, has been reported 
to occur 5-7 days after injection BALB/c and outbred Sabra mice [29]. Two NSG mice were 
injected in this study. Mice were found dead without showing signs of physical abnormalities 
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or weight loss. It was judged unethical to inject more mice with this formulation. On the other 
hand, all mice injected with 0.5 µmol L-ALD (n = 10) showed 100% survival over the entire 
study duration (24 days). 
 
3.7 Multiple and single dosing of L-ALD show comparable in vivo toxicity profiles in 
NSG mice 
To mimic dosing regimen used in combination N-BP and γδ T cell immunotherapy studies, 
multiple dosing of L-ALD, with weekly intervals, was performed. The overall in vivo toxicity 
was compared to that of single administration. Mice were sacrificed 72 h after the final 
injection. The spleen weights (Figure 6A), haematology (Figure 6B-D and Table S4) and 
biochemistry (Table S5) profiles were not significantly different from values obtained with 
single L-ALD injection. This suggests that the toxicity from L-ALD was not cumulative. 
 
3.8 In vivo whole body SPECT/CT imaging of EL 
The effect that placing N-BPs into liposomes would have on their biodistribution was then 
studied. The cell line A375Pβ6 was chosen due to its favourable in vivo growth and greater 
ability to be sensitised to γδ T cells by L-ALD than the other cell lines screened. Liposomes 
were formulated to include 1% DSPE-DTPA and were labelled with 
111
In, which did not 
affect the physicochemical properties of the liposomes (data not shown). Initial labelling of 
86.3 % was achieved and in the presence of PBS or 50 % FBS, 87.8 and 91.1 % remained 
bound to the EL after 24 h, respectively (Figure S13). Whole body SPECT/CT images of 
intravenously injected [
111
In]EL in A375Pβ6 subcutaneous tumour-bearing NSG mice were 
performed in order to track the biodistribution of EL over time. The mice were imaged at 
multiple time points up to 24 h post-injection as shown in Figure S14. At early time-points, 
EL displayed high concentrations in the circulation, with activity located throughout the 
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mouse at 0-30 min and to a slightly lesser extent at 4 h. At 24 h, accumulation of [
111
In]EL in 
liver and spleen was observed. The uptake in A375Pβ6 tumour could not be observed by this 
imaging modality, possibly due to prolonged blood circulation of the [
111
In]EL. 
 
3.9 L-ZOL and L-ALD show similar tumour and organ biodistribution patterns in vivo. 
The organ biodistribution and tumour uptake profiles of [
111
In]EL, [
111
In]L-ZOL and [
111
In]L-
ALD following i.v. injection were assessed quantitatively by γ-scintigraphy in A375Pβ6 
subcutaneous tumour-bearing NSG mice. This was done in order to help understand the 
toxicity results obtained. Prolonged blood circulation profiles were not significantly different 
between the 3 formulations, with 71-81, 52-58 and 15-26 %ID remaining in the blood at 1 h, 
4 h and 24 h, respectively (Figure 6A). Agreeing with SPECT/CT images, the liver and 
spleen were the organs with the highest liposome accumulation (Figure 6B). Liver uptake 
was 23.5 ± 6.5, 25.4 ± 7.2 and 18.7 ± 2.7 % ID/g for [
111
In]EL, [
111
In]L-ZOL and [
111
In]L-
ALD, respectively, at 24 h.  Spleen uptake was 55.8 ± 13.6, 144.1 ± 70.5 and 148.9 ± 61.1 
%ID/g for the same formulations.  Both [
111
In]L-ZOL and [
111
In]L-ALD  showed 
significantly 3-fold higher spleen uptake than [
111
In]EL, with no significant differences seen 
between [
111
In]L-ZOL and [
111
In]L-ALD. No significant differences in tumour uptake 
between the three formulations were found (~1.9 – 3.1 % ID/gram) (Figure 6B, inset).  The 
organ biodistribution profiles expressed as % ID/organ are displayed in Figure S15. We 
believe that any differences in in vivo toxicity are not likely due to differences in 
pharmacokinetic profiles, since all liposomes exhibited similar size and surface charge.   
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
27 
 
 
 
Figure 6: In vivo biodistribution of radiolabelled EL, L-ALD and L-ZOL in A375Pβ6 tumour 
bearing NSG mice after single dose administration via tail vein injection. NSG mice were 
inoculated bifocally with the A375Pβ6 cell line and were i.v. injected with 
111
In labelled liposomes at 
a dose of 2 μmol lipid/mouse. (A) Blood clearance profile of liposomes expressed as %ID. (B) Results 
were expressed as percentage injected dose per gram of organ (%ID/g organ) at 24 h after injection of 
2 μmol liposome/mouse. L-ZOL and L-ALD was seen to have higher spleen accumulation than EL. 
Data are expressed as mean ± SD (n=3) *p < 0.05, **p < 0.01.  (Student’s t test vs. naive).  
 
3.10 Combinatory L-ALD and γδ T cell immunotherapy  
To assess whether the dosing regimen of L-ALD used in the toxicity studies was sufficient to 
result in the potentiation of the immunotherapy, a tumour growth delay experiment was 
performed in the pseudo-metastatic lung tumour model, following i.v. administration of both 
therapeutic agents. At the start of treatment (day 6), all four groups (naïve, L-ALD, γδ T cells 
and L-ALD + γδ T cells) had the same average tumour size (3.4 x 106 photons). After three 
treatments at one week intervals (day 28), the tumour sizes were 6.9 x 10
9 
± 1.5 x 10
9 
(naïve), 
3.5 x 10
9 
± 1.6 x 10
9
 (L-ALD), 5.3 x 10
9 
± 1.0 x 10
9
 (γδ T cells), and 2.1 x 109 ± 8.2 x 108 (L-
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ALD + γδ T cells) photons (Figure 4). Although monotherapy of L-ALD or γδ T cells 
resulted in some tumour growth delay, only the combination treatment demonstrated a 
significant reduction in tumour growth (p = 0.015) with a ~3-fold decrease in tumour growth.   
 
 
 
 
 
 
 
 
 
 
 
Figure 7: In vivo tumour therapy study. Pseudo-metastatic lung A375Pβ6 tumour bearing mice 
were treated with L-ALD (0.5 µmol ALD/mouse), 1 x 10
7
 γδ T cells/mouse or both, intravenously. 
Three treatments were given intravenously at one week intervals, commencing on day 6 post-tumour 
inoculation. Tumour progression was monitored by bioluminescence imaging. A significant reduction 
in tumour growth was observed for the combinatory immunotherapy. Data was expressed as mean ± 
SEM (n=7). *p < 0.05, (Student’s t test vs. naïve). 
 
3.11 IFN-γ detected in sera of mice treated with γδ T cells and L-ALD  
In order to determine whether L-ALD had activated of γδ T cells in vivo, the release of IFN-γ 
from the γδ T cells was measured. Analysis of sera samples from mice demonstrated 
detectable levels of human IFN-γ in the sera of the combinatory group only (9.2 ± 5.1 pg/ml). 
In the case of mice treated with γδ T cells alone, an insufficient amount of human IFN-γ was 
released to be detected. 
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4. Discussion 
N-BPs have been shown to effectively sensitise various cancer types to Vγ9Vδ2 T cells in 
both preclinical [19, 21-26] and clinical studies [44-47]. Due to the known limitations of the 
pharmacokinetics of bisphosphonates [28], encapsulating these agents within liposomes 
offers an attractive solution to increase delivery of bisphosphonates to non-osseous tumour 
sites.  ZOL is the most potent of the N-BPs [48, 49] and is the most widely used 
bisphosphonate in γδ T cell immunotherapy studies. However, in a study by Shmeeda et al. 
[29], it was shown that while encapsulating ZOL in liposomes increased the amount of ZOL 
in tumours in vivo, mice unexpectedly died 5-7 days after treatment with this formulation. 
This toxicity was also reported by co-authors of this work [23]. In this study, an alternative 
bisphosphonate, ALD, in the liposomal formulation was used and did not result in mice death 
at a therapeutically efficacious dose in an intraperitoneal ovarian tumour model. As we have 
also shown in a pseudo-metastatic lung melanoma tumour model (Figure 7), significant 
inhibition of tumour growth was observed when L-ALD was used in combination with γδ T 
cells. A liposomal formulation of ZOL that was shown to increase survival time of prostate 
tumour-bearing mice with no toxicity observed, has also been reported [50]. However, this 
formulation was composed of Egg PC, DSPE-PEG2000 and cholesterol and had also been 
exposed to freeze-drying. When comparing the results of this study to their own, Shmeeda et 
al., suggested that the use of use of Egg PC and freeze drying led to a less stable formulation , 
and this could be the reason for the discrepancy in toxicity in vivo work [29]. A hybrid 
nanoparticle-liposome formulation has also been prepared consisting of a calcium phosphate 
core to which ZOL could bind mixed with DOTAP/cholesterol/DSPE-PEG2000 liposomes 
[37]. These hybrid particles achieved a significant tumour weight inhibition of 45 %, and 
while no in vivo toxicity tests were performed, no sudden mouse death was observed [38]. 
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L-ALD has also been used in vivo, as a monotherapy for a murine breast cancer model [31]. 
However, while some tumour growth inhibition was observed this did not reach significance, 
similarly to what we observe in this work. This suggests that ALD does not reach sufficient 
concentrations in tumours to be therapeutically efficacious as a monotherapy, even when 
encapsulated in a liposomal formulation.  L-ALD has also been used in the treatment of 
inflammatory conditions [32-35]. The ability of ALD liposomes to deplete monocytes and 
macrophages has been shown to inhibit restenosis and endometriosis in a rat model [35]. This 
anti-inflammatory activity of ALD liposomes has shown to be effective in the inhibition of 
restenosis in rabbits in vivo [30]. These liposomes were negatively charged due to the 
inclusion of distearoyl-phosphatidylglycerol (DSPG), and had a zeta potential of 
approximately -29 mV. Additionally, a clinical trial involving the use of L-ALD in coronary 
artery restenosis prevention is due to commence this year [36]. ALD has also been co-
encapsulated with doxorubicin (DOX) into liposomes [39]. Liposomes encapsulating both 
drugs were shown to be more effective than liposomes encapsulating DOX alone at inhibiting 
tumour growth in 4T1 breast cancer and M109R lung cancer models in BALB/c mice in vivo. 
While γδ T cells were not used in this study, the in vivo toxicity of L-ALD was also examined 
with the incorporation of ALD in liposomes shown to lead to a 40 fold increase in IL-1β 
secretion from monocytes in vitro, but did not activate the complement system in human 
plasma [39]. Although L-ALD has been assumed to be safe substitute for L-ZOL, 
comparative in vivo toxicity studies have not been performed. In the current report, we 
examine the ability of L-ALD to substitute L-ZOL, as a γδ T cells sensitiser in vitro, followed 
by conducting a comparative in vivo toxicity study for both formulations after single i.v. 
injection, at therapeutically relevant doses in mice. In vivo L-ALD toxicity, following 
multiple i.v. injections, mimicking the immunotherapy therapy protocol, was also assessed. 
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Organ biodistribution studies of empty and N-BP loaded liposomes were performed in order 
to help partially understand findings of the in vivo comparative toxicity study.  
 
ALD and ZOL are second and third generation N-BPs, respectively [51]. In our studies we 
have seen that ZOL is ~5 times more potent as both a monotherapy and as a sensitising agent 
for γδ T cell immunotherapy. Similar findings in relation to the potency of the two N-BPs 
have been reported in the literature. ZOL had IC50 values of 0.02 ± 0.00 µM for inhibition of 
FPP synthase in J774 cell homogenates and 0.003 ± 0.000 µM for inhibition of recombinant 
human FPP synthase. ALD, however had IC50 values of 0.50 ± 0.15 µM and 0.05 ± 0.001 
µM, respectively. The necessity to use increased concentrations of L-ALD compared to L-
ZOL is consistent with these findings. A study that compared four different formulations of 
L-ZOL on their cytotoxic ability found that unless the liposomes were targeted to the folate 
receptor, a reduction in cell viability was not observed at concentrations up to 200 µM [52]. 
However, this study was looking at the direct cytotoxic action of ZOL as a monotherapy. 
Much lower concentrations of ZOL are required to sensitise cancer cells to γδ T cells hence 
in our study we did not explore the active targeting approach and much lower concentrations 
of ZOL were used.  L-ALD however seems to exhibit higher IC50 values than L-ZOL so 
utilisation of active targeting approach for this type of formulation in the future is worth 
investigating, to establish if lower L-ALD doses, which are more relevant for in vivo settings, 
can be used. Co-authors of this work have previously studied the ability of L-ZOL and L-
ALD to sensitise the ovarian cancer cell line IGROV-1 to destruction by γδ T cells in vitro 
[23]. L-ZOL (0.1µg/ml, ~0.25 µM) and L-ALD (0.2µg/ml, ~0.6 µM) led to ~ 25 % apoptotic 
cells and ~ 30 % reduction in cell viability when used in combination with γδ T cells, at much 
lower concentrations than used in our study (3-10 µM and 40-60 µM for L-ZOL and L-ALD 
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respectively). These are much lower concentrations than used in our study (3-10 µM and 40-
60 µM for L-ZOL and L-ALD respectively) but cell lines used are also different. 
 
In the present study, and for the first time, we directly compared the in vivo toxicity of L-
ZOL and L-ALD. Based on the results of the in vitro assays, L-ALD were used at a 
concentration five times higher (0.5 µmol/mouse) than that of L-ZOL (0.1 µmol/mouse). The 
dose of L-ALD used matches that used in the study by Parente-Pereira et al. [23]. Shmeeda et 
al. assessed the toxicity of L-ZOL in BALB/c and Sabra mice [29], and it was shown that L-
ZOL resulted in splenomegaly (~200 mg vs. 120 mg/spleen [29]) and leucocytosis (~30 x 10
3
 
WBC/µl vs. ~5 x 10
3
 WBC/µl [29]). Despite the different stain of mice used in this study, 
similar increases in spleen weight (0.06 ± 0.02 g vs. 0.03 ± 0.004 g) and WBC concentration 
(3.22 ± 2.49 10e
9
/L vs. 0.77 ± 0.15 10e
9
/L) were observed (Figure 7). Macrophage depletion, 
as a result of liposomal BPs administration, has been reported to lead to splenomegaly [53]. 
Additionally there were several differences between the result reported here and the results of 
Shmeeda et al., with no reduction in platelet number or haemoglobin observed in our study 
unlike their previous report [29]. Different time points at which the mice were sacrificed 
post-injection were used (3 days vs. 5 days [29]). Consistent to what we report here, the 
toxicity of L-ALD has been shown to be non-cumulative after multiple injections by Gabizon 
and co-workers [39]. Despite the comparable in vivo toxicity profiles of L-ALD and L-ZOL, 
L-ALD and L-ZOL resulted in 100% and 0% mice survival, respectively, at the studied 
doses. NSG mice are not the best models to carryout toxicity studies for two reasons; they are 
known to have several defects in cytokine signalling pathways [54]. Secondly, it was 
previously hypothesised that the mechanism of in vivo L-ZOL toxicity is linked to cytokine 
release from macrophages [29].  It is therefore interesting to observe comparable L-ZOL 
toxicity profiles in both immunocompetent and immunocompromised mice. Such puzzling 
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results cannot be explained using the results presented here. A previous study by Parente-
Pereira et al. [23] used the same dosage regimen of L-ALD and showed no mice death. 
However, no toxicity profiling was carried out in that study. Different markers for in vivo 
toxicity may need to be assessed in order to be able to differentiate between the toxicity of L-
ZOL and L-ALD. For example, in rat and rabbit models, complement and IL-2β markers 
after injection of L-ALD have been studied in vivo [55]. L-ALD led to increased secretion of 
IL-2β in both rat and rabbit, with minor complement activation seen in rat only. However, the 
liposomes in these studies were more negatively charged that those used in our study, which 
may lead to differences in in vivo toxicity. Similar studies have not been undertaken for L-
ZOL.    
 
The formulation of the liposomes can also influence their in vivo behaviour. In this study, the 
size of the liposomes is within the range (100 – 200 nm) reported to be extravasated in 
regions of leaky vasculature as part of the EPR effect [56] and the low PDI values indicate 
that the liposomes are homogenous. The L-ZOL and L-ALD obtained have similar 
physicochemical characteristics and drug loading, allowing for direct comparisons to be made 
between them (Table S1). In order to better understand the results of the in vivo toxicity 
studies, the biodistribution of EL, L-ZOL and L-ALD in tumour bearing mice was studied. A 
three-fold increase in the spleen uptake of both L-ALD and L-ZOL was observed compared 
to EL. The increase in spleen uptake of L-ALD in comparison to liposomal doxorubicin has 
been previously reported [39]. The spleen uptake of L-ALD has not been compared to L-ZOL 
previously and it was not known whether a difference in spleen uptake of the two 
formulations could account for the increased toxicity of L-ZOL. Our results confirmed no 
significant differences in spleen uptake between the uptake of L-ZOL and L-ALD. Such 
results at least concluded that the sudden mice death in case of L-ZOL was not due to this 
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higher uptake in spleen. The increased spleen uptake may be as a result of the well-reported 
macrophage depletion properties of liposomal N-BPs [32, 57], whereby macrophages that 
uptake L-ZOL or L-ALD undergo macrophage apoptosis [58]. This would result in the 
trafficking of damaged macrophages containing L-ZOL or L-ALD to the spleen [59], which 
also explains the higher levels of radioactivity detected in the spleen than EL (Figure 6). 
Furthermore, this may account for the significant increase in spleen weight observed in mice 
injected with L-ZOL or L-ALD (Figure 5). Interestingly, despite the higher accumulation of 
L-ZOL or L-ALD in the spleen no histological changes were observed in the spleen tissues. 
The biodistribution of L-ZOL has previously been reported [29], but empty liposomes were 
not used as a control in this study. Once again, however, no discernible differences between 
L-ZOL and L-ALD were observed that may account for the differences in toxicity of these 
two formulations. Liposomal formulations of drugs were originally proposed to reduce 
systemic toxicity of drugs. The increased toxicity of ZOL when it was encapsulated into 
liposomes contrasts the original purpose of its nanoformulation and highlights the importance 
of considering the free drug and its nanoformulation as two separate entities.  
 
In our study, combinatory γδ T cell immunotherapy was shown to significantly reduce 
tumour growth in a pre-clinical mouse model. Mice treated with L-ALD and γδ T cell 
showed a ~3-fold decrease in tumour growth when compared to naïve mice (p > 0.05). L-
ALD has not yet been used in combination with γδ T cells in clinical studies.  Only one study 
has been done on the use of L-ALD in combination with human γδ T cells, by co-authors of 
this work [23]. In the reported study, Parente et al. used L-ALD in combination with human-
derived γδ T cells to treat an intraperitoneal ovarian cancer model in mice [23]. Significant 
reductions in tumour growth was observed in mice injected with both L-ALD and γδ T cells. 
Our study utilised the same L-ALD and γδ T cells doses reported by Parente et al., but the 
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route of γδ T cells administration was different; Parente et al. injected γδ T cells 
intraperitoneally while in our study cells were injected intravenously. Both studies however 
concluded that L-ALD was necessary to improve the potency of γδ T cells immunotherapy. 
 
Clinically, γδ T immunotherapy has been used for the treatment of renal cell carcinoma [7, 8, 
45], multiple myeloma [6], non-small cell lung cancer [11, 60] and other various solid 
tumours [9, 10], with disease stabilisation achieved in the majority of these studies. However, 
N-BPs were not used in most of these studies, suggesting that the full potential of γδ T 
immunotherapy has yet to be explored. While there is a clinical trial for L-ALD due to 
commence as a monotherapy [36], its use as a sensitiser for γδ T immunotherapy in cancer 
has yet to be assessed in humans. It is also possible that L-ALD may also have anti-cancer 
activities unrelated to γδ T cell sensitisation. A direct cytotoxic effect may not have a 
significant therapeutic effect at the dose used. However, the ability of L-ALD to lead to 
monocyte and macrophage depletion has been well reported and has shown benefits in the 
treatment of restenosis and endometriosis [55, 61]. This aspect of L-ALD activity may help 
contribute to its anti-cancer properties as high levels of macrophages in the tumour have been 
associated with disease progression and treatment resistance [62].  
 
5. Conclusion 
While some toxic side effects were seen after injection of L-ALD, namely increased spleen 
weight, leucocytosis, neutrophilia and lymphocytopenia, mice injected with L-ALD had a 
100 % survival rate while L-ZOL resulted in mice death.  Despite L-ALD being ~5 times less 
potent than L-ZOL at sensitising tumour cells to destruction by γδ T cells in vitro, it is 
evident from the in vivo therapy study that therapeutically relevant concentrations of L-ALD 
and γδ T cells could be achieved in tumour tissues, following systemic administration. L-
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ALD has been shown to be efficacious as a sensitiser for γδ T cell immunotherapy, and the 
combinatory therapy resulted in activation of γδ T cells and delayed tumour growth in a 
pseudo-metastatic lung mouse model.  
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Figure 1: IC50 values of N-BPs after 72 h incubation for different human cancer cell 
lines.  The IC50 values were determined for the melanoma cancer cell line A375Ppuro and the 
pancreatic cancer cell line PANC-1 incubated with (A) ZOL or (B) ALD for 72 h. IC 50 are 
in the order of PANC-1 > A375Ppuro for both ALD and ZOL.  Higher IC50 values were 
obtained for ALD than ZOL. R
2
 values of 0.9988 (ALD PANC-1 and ZOL A375Ppuro). 
0.9736 (ALD A375Ppuro) and 0.9718 (ZOL PANC-1) were obtained. Data was expressed as 
mean ± SD (n=5).  
 
Figure 2: Viability of human cancer cell lines after incubation with γδ T cells and L-
ZOL. Cells were treated with ZOL or L-ZOL for 24h at concentrations between 3-10 µM. 
The treatments were then removed and replaced with 2 x 10
5
 γδ T cells for an additional 24h, 
before an MTT assay was performed to determine residual tumour cell viability. The ZOL 
and L-ZOL were used at non-toxic concentrations, in the absence of γδ T cells. No 
background toxicity was found for γδ T cells without N-BP. However, a dose dependent 
toxicity was found in cells pre-treated with ZOL or L-ZOL (ZOL> L-ZOL), except for 
PANC0403. Data was expressed as mean ± SD (n=5). *p < 0.05, (Student’s t test vs. naive). 
 
 
Figure 3: Cell viability of human cancer cell lines after incubation with γδ T cells and L-
ALD. Cells were treated with ALD or L-ALD for 24h at concentrations between 40-60 µM. 
These agents were then removed and replaced with 2 x 10
5
 γδ T cells for an additional 24 h, 
before an MTT assay was performed to measure residual tumour cell viability. The ALD and 
L-ALD were used at non-toxic concentrations, in the absence of γδ T cells. No background 
toxicity was found for γδ T cells without N-BP. However, a non-dose dependent toxicity, in 
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the range tested, was found in cells pre-treated with ALD or L-ALD (ALD> L-ALD). Data 
was expressed as mean ± SD (n=5). *p < 0.05, (Student’s t test vs. naive). 
 
Figure 4: IFN-γ production by γδ T cells after incubation with cancer cells. IFN-γ ELISA 
was performed on supernatant removed from the co-culture experiment, prior to the MTT 
assay, for each of the cancer cell lines. The quantity of IFN-γ produced by the γδ T cells for 
each of the different pre-treatment conditions is expressed as ng/ml. Free ZOL or ALD led to 
an increased production of IFN-γ compared to γδ T cells incubated with untreated cells. 
Pretreament with L-ZOL or L-ALD led to a smaller or no increase in IFN-γ production. Data 
was expressed as mean ± SD (n=3). *p < 0.05, **p < 0.01, ***p < 0.001.  (Student’s t test vs. 
γδ T cells alone).  
 
Figure 5: Effects of L-ZOL and L-ALD on blood counts and spleen. NSG mice were 
injected with 0.1 µmol L-ZOL or 0.5 µmol L-ALD. After 72 h, the mice were sacrificed. (A) 
The spleen was removed and weighed. A significant increase in spleen weight could be seen 
in the case of both L-ZOL and L-ALD.  Blood counts were performed by automatic counting. 
An increase in (B) WBC and (C) % Neutrophils was seen when injected with L-ZOL or L-
ALD, while a decrease in (D) % Lymphocytes was observed. (Data were expressed as mean 
± SD (n=10 and n=5 for spleen weight and blood counts, respectively) *p< 0.05, **p< 0.01, 
***p< 0.001.  (Student’s t test vs. naive). 
 
 
Figure 6: In vivo biodistribution of radiolabelled EL, L-ALD and L-ZOL in A375Pβ6 
tumour bearing NSG mice after single dose administration via tail vein injection. NSG 
mice were inoculated bifocally with the A375Pβ6 cell line and were i.v. injected with 
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labelled liposomes at a dose of 2 μmol lipid/mouse. (A) Blood clearance profile of liposomes 
expressed as %ID. (B) Results were expressed as percentage injected dose per gram of organ 
(%ID/g organ) at 24 h after injection of 2 μmol liposome/mouse. L-ZOL and L-ALD was 
seen to have higher spleen accumulation than EL. Data are expressed as mean ± SD (n=3) *p 
< 0.05, **p < 0.01.  (Student’s t test vs. naive).  
 
Figure 7: In vivo tumour therapy study. Pseudo-metastatic lung A375Pβ6 tumour bearing 
mice were treated with L-ALD (0.5 µmol ALD/mouse), 1 x 10
7
 γδ T cells/mouse or both, 
intravenously. Three treatments were given intravenously at one week intervals, commencing 
on day 6 post-tumour inoculation. Tumour progression was monitored by bioluminescence 
imaging. A significant reduction in tumour growth was observed for the combinatory 
immunotherapy. Data was expressed as mean ± SEM (n=7). *p < 0.05, (Student’s t test vs. 
naïve). 
 
 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
45 
 
Graphical abstract 
 
TOC figure 
